President Donald Trump reached deals with 16 leading pharmaceutical companies aimed at aligning U.S. prescription drug prices with those in other developed countries. In return, these companies received three-year exemptions from tariffs on imported medications.
Under the agreements, drugmakers committed to “most-favoured-nation” pricing, agreed to sell medications directly to consumers via a new government platform called TrumpRx.gov, and pledged billions of dollars in investment in the United States.
Read Also – UK NHS to Provide Weight-Loss Injection Wegovy for Individuals at Risk of Heart Attack and Stroke
In July, Trump sent letters to the heads of 17 major pharmaceutical companies, demanding that the prices of their new drugs in the U.S. match the lowest prices offered in other developed countries. Following this, 16 of the companies publicly confirmed that they had reached agreements with the government.
PFIZER
In September, the company agreed to reduce prescription drug prices for American patients, offering discounts of up to 85% through TrumpRx.gov.
Pfizer stated that most of its primary care medications, along with select brands such as the rheumatoid arthritis drug Xeljanz, dermatitis treatment Eucrisa, and post-menopausal osteoporosis medicine Duavee, would be available at average savings of around 50%, with some discounts reaching as high as 85%.
JOHNSON & JOHNSON
In January, drugmaker J&J agreed to reduce prescription drug prices for American patients, including through the TrumpRx.gov platform.
The specific terms of the agreement, such as the exact price reductions and which medications are included, were not publicly disclosed.
ASTRAZENECA
In October, AstraZeneca agreed to reduce prescription drug prices for American patients, offering discounts of up to 80% through the TrumpRx.gov platform.
NOVO NORDISK
In November, weight-loss drug maker Novo Nordisk (NOVOb.CO) agreed to lower prices for its semaglutide medications, including Wegovy and Ozempic, for American patients via the government’s Medicare, Medicaid, and a direct-to-patient cash channel.
Under the agreement, Ozempic and Wegovy prices will drop from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.
Novo Nordisk will offer widely used insulin products, such as NovoLog and Tresiba, at $35 per month through the same platform.
ELI LILLY
In November, Eli Lilly agreed to provide Medicare beneficiaries with its obesity medications Zepbound and orforglipron, marketed as Foundayo, at a maximum of $50 per month. Additional discounts will be available for self-paying patients through LillyDirect.
The Zepbound multidose pen will start at $299 per month for the lowest dose, with higher doses priced up to $449. Foundayo will be offered starting at $149 per month at its lowest dose via LillyDirect.
Lilly will make its migraine treatment Emgality available at $299 per pen, and the diabetes medication Trulicity at $389 per month through the TrumpRx platform.
ABBVIE
In January, AbbVie agreed to reduce drug prices for American patients through Medicaid and to expand direct-to-patient access via the TrumpRx platform for medications including Humira and Synthroid
MERCK
In December, U.S. pharmaceutical company Merck announced that it will offer its diabetes medications—Januvia, Janumet, and Janumet XR, which are expected to face generic competition next year—directly to American consumers at approximately 70% off the list prices.
Additionally, if approved, Merck’s experimental cholesterol drug, enlicitide, will also be made available through direct-to-consumer channels, including the TrumpRx platform.
ROCHE
In December, Roche’s subsidiary Genentech announced that it would reduce prices for many of its medications under Medicaid to levels comparable with those in other developed countries.
The company also agreed to offer its influenza treatments through the TrumpRx.gov platform as well as via its own direct-to-patient program.
NOVARTIS
In December, Novartis announced that it would introduce new drugs in the U.S. at prices aligned with those in other developed countries.
The company also agreed to provide its multiple sclerosis medication Mayzent, along with cancer treatments Rydapt and Tabrecta, through both its direct-to-patient platform and the TrumpRx.gov program.
GSK
GSK (GSK.L) announced that it would make the majority of its inhaled respiratory medications and other treatments available directly to patients through a direct-to-patient platform, offering savings of up to 66%.
The company also committed to reducing prices for certain medicines under Medicaid and to launching new drugs in the U.S. with a “more balanced pricing approach” consistent with other developed countries.
REGENERON
Regeneron stated in April that it expects to finalize an agreement with the Trump administration “in the near future.”
It remains the only company among the 17 major pharmaceutical firms that received letters from President Donald Trump in July that has not yet signed such a deal.
